- Home
- ELVR vs JANX Comparison
ELVR vs JANX Comparison
Compare ELVR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVR | JANX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Australia | United States |
| Employees | 230 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 975.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELVR | JANX |
|---|---|---|
| Price | $55.55 | $16.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 43.2K | ★ 721.4K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $90.73 | N/A |
| Revenue Next Year | $42.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.55 | $12.12 |
| 52 Week High | $102.80 | $35.34 |
Technical Indicators
Market Signals| Indicator | ELVR | JANX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout ELVR Sayona Mining Limited American Depository Shares
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.